Navigation Links
Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
Date:9/28/2007

CALGARY, Sept. 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REOLYSIN(R) and radiation clinical trial for patients with advanced or metastatic cancers is scheduled to be presented at the National Cancer Research Institute (NCRI) conference on October 2, 2007 in Birmingham, U.K. The presentation, entitled "Biological Approaches to Radiosensitisation: Viruses, Gene Therapy and Novel Radiosensitisers" will be presented by Dr. Kevin Harrington of The Institute of Cancer Research, London and one of the principal investigators for the trial. The conference runs from September 30 through October 3, 2007 in Birmingham, U.K.

"We are very pleased with the results of this trial to date," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to evaluate the data and look forward to announcing final results."

To date, 22 patients have been treated with 15 having completed the study. Five patients withdrew from the study, and two patients are still on study.

A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of REOLYSIN(R) at dosages of 1x10(8), 1x10(9), or 1x10(10) TCID(50) with a constant localized radiation dose of 20 Gy given in five fractions. Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.

One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target tumour, with stable disease noted in four, non-treated tumours. At two and three months, the target tumour had shrunk 64%, with stable disease continuing in the four non-treated tumours, including a 15% volume reduction in non-treated mediastinal disease that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction in the t
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... the "Top Technologies in HW_Technical Insights" report ... this report evaluated technology trends in the Health and ... are likely to have an impact in the year ... of the top 10 health and wellness technologies that ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2
... MUNICH, Feb. 1, 2012  Exosome Diagnostics GmbH, a ... of Dermatology at the Ludwig Maximilian University (LMU) ... grant from the German Federal Ministry for Education ... from the stable RNA content accessible in plasma-derived ...
... WASHINGTON and SAN DIEGO, Feb. 1, 2012 /PRNewswire-iReach/ ... will be exhibiting at the CRT 2012 Conference in ... showcase its new cardiovascular diagnostic test PREvent. PREvent is ... the market that predicts near term (2-3 years) risk ...
... 2012   PAREXEL International Corporation (NASDAQ: ... today that it has entered into an agreement with ... Korea. The alliance offers clinical trial sponsors based regionally ... services throughout Asia , with a focus on ...
Cached Biology Technology:EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 2EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 3EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 4FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 3PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 4PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 5
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... Managing plant diseases that threaten the food supply ... world. Sparsely stocked libraries, scarce and expensive software, ... languages are barriers to training plant pathologists in resource-poor ... University professor and her colleagues is bridging that gap. ...
... materials have garnered great interest worldwide due to ... medical and consumer applications. Singapore,s Institute ... new environmentally friendly method to synthesize a wide ... has been recently published in Nature Materials ...
... LAFAYETTE, Ind. - Using a diverse herbicide application strategy ... study shows the practice will drastically reduce weeds and ... Excess usage of glyphosate-resistant crops has led to weeds, ... the herbicide used in Roundup. Bill Johnson, a Purdue ...
Cached Biology News:K-State plant pathologists develop online teaching modules used globally 2Facile synthesis of nanoparticles with multiple functions advanced in Singapore 2Herbicide diversity needed to keep Roundup effective 2
... Antibody against TATA Binding Proteins (TBP). Ascites ... TBP and recognizes amino acids 41-57 and ... fragmentation of TBP occurs. This antibody ... (prepared either as a nuclear extract or ...
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... The CHEMICON Re-Blot Plus Western Blot Strong ... of antibodies from Western blots that have ... or other isotopes. It is not recommended ... etc.), as it is not possible to ...
Biology Products: